Edition:
United States

National Investments Fund Ltd (1227.HK)

1227.HK on Hong Kong Stock

0.14HKD
23 Mar 2017
Change (% chg)

HK$0.00 (+0.00%)
Prev Close
HK$0.14
Open
HK$0.14
Day's High
HK$0.14
Day's Low
HK$0.14
Volume
2,680,000
Avg. Vol
45,061,303
52-wk High
HK$0.55
52-wk Low
HK$0.05

Latest Key Developments (Source: Significant Developments)

National Investments Fund expects to record FY loss attributable
Thursday, 16 Mar 2017 05:24am EDT 

National Investments Fund Ltd <1227.HK> : Expected to record a loss attributable to owners of company for year ended 31 december 2016 .Expected loss was mainly attributable to other operating expenses and finance costs.  Full Article

National Investments Fund enters into placing agreement
Tuesday, 28 Feb 2017 06:05am EST 

National Investments Fund Ltd <1227.HK> : Company and placing agent entered into placing agreement . Placing agent has agreed to place, up to 110 million shares at placing price of HK$0.142 per placing share .Estimated net proceeds from placing will be approximately HK$15.15 million.  Full Article

National Investments updates on acquisition of Cryolife by Medisun
Monday, 20 Feb 2017 05:37am EST 

National Investments Fund Ltd <1227.HK> :Unit entered into sale and purchase agreement with independent third party to acquire 51% of cryolife holdings, on 16 february.  Full Article

National Investments Fund Ltd enters into placing agreement
Tuesday, 20 Dec 2016 05:56am EST 

National Investments Fund Ltd <1227.HK> : Placing agent has agreed to place, on a best effort basis, up to 48 million shares at placing price of HK$0.113 per placing share .Company and placing agent entered into placing agreement.  Full Article

National Investments Fund - Celyad enters into license agreement with ono pharmaceutical co., ltd. to develop allogeneic nkr-2 t-cell immunotherapy<1227.HK><4528.T>
Wednesday, 13 Jul 2016 05:54am EDT 

National Investments Fund Ltd <1227.HK>: Celyad enters into license agreement with Ono Pharmaceutical Co., Ltd. to develop allogeneic nkr-2 t-cell immunotherapy . Celyad would receive upfront payment of $12.5 million and is eligible of up to $299 million in development and commercial milestones . Celyad would also receive double digit royalties based on net sales of the licensed product in ono's territories . Under the agreement, Celyad would continue developing its allogeneic nkr-2 t-cell immunotherapy in EU and US territories . Says company is aware that Celyad s.a had published a press release on 11 July 2016 .  Full Article

National Investments Fund Ltd issues fy 2015 Profit warning
Wednesday, 16 Mar 2016 04:27am EDT 

National Investments Fund Ltd:National investments fund-group is expected to record a loss attributable to owners of the company for the year ended 31 December 2015.Loss was mainly attributable to decrease in revenue.  Full Article

National Investments Fund Ltd says resignation of CEO
Monday, 31 Aug 2015 08:10am EDT 

National Investments Fund Ltd:Says Tian Jingjing has tendered her resignation as the Chief Executive Officer of the Company with effect from 31 August 2015.  Full Article

More From Around the Web

BRIEF-National Investments Fund expects to record FY loss attributable

* Expected to record a loss attributable to owners of company for year ended 31 december 2016

No consensus analysis data available.